Timing of early treatment for resistant bacterial infections in blood cancer patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at when to start antibiotics early for blood cancer patients who may be carrying resistant bacteria (that are hard to treat). It aims to find the best time to treat these infections to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are being treated in the hospital for a blood cancer (like leukemia or lymphoma) with chemotherapy, immunotherapy, or a stem cell transplant.
- You have had a recent test showing you carry resistant bacteria, or you are being tested for it each week while in the hospital.
- Your doctor thinks you have a high risk of a resistant bacteria infection and you need intravenous antibiotics that can fight these resistant bacteria.
- You have a fever or other signs of infection, and your white blood cell count is very low (a condition called neutropenia) that is expected to last for 7 days or more.
- You also have at least one of these: severe gut problems, shock, breathing failure, blood clotting problems, confusion, heart failure, or a new fever despite recent antibiotic treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients with blood cancers who may carry bacteria that are resistant to many antibiotics. It aims to find which patients are more likely to get sick from these bacteria, so doctors can better protect them.
This trial compares stopping antibiotics early (after fever resolves) versus continuing them as usual in adults with blood cancers who develop fever during treatment. It aims to find the best timing to reduce unnecessary antibiotic use.
This study looks at how long antibiotics should be given to cancer patients with fever and very low white blood cell counts after finding a certain type of bacteria (Gram-negative) in their blood. The goal is to find the best treatment duration to help patients recover without complications.
This study looks at how doctors can best manage antibiotics for a common type of blood infection (caused by Enterobacterales bacteria like E. coli). If you join, your treatment will be carefully guided to make sure you get the right antibiotics at the right time, which may help you recover faster and prevent antibiotic resistance.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Hear when a new Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.